%0 Generic
%A Powles, T. B.
%A Chistyakov, V.
%A Beliakouski, V.
%A Semenov, A.
%A Everaert, E.
%A Baranau, Y.
%A Moreno, V.
%A Valderrama, B. Perez
%A Vano, Y.
%A Del Conte, G.
%A Loriot, Y.
%A Kang, T. W.
%A Tammaro, M.
%A O'Hagan, A.
%A Hosseini, M.
%A Triantos, S.
%A Chhabra, H.
%A Santiago-Walker, A.
%A Siefker-Radtke, A. O.
%T Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
%D 2021
%@ 0923-7534
%U https://hdl.handle.net/10668/27230
%~